33,749,997 Ordinary Shares of Citi Pharma Limited are subject to a Lock-Up Agreement Ending on 24-JUN-2022.
June 23, 2022
Share
33,749,997 Ordinary Shares of Citi Pharma Limited are subject to a Lock-Up Agreement Ending on 24-JUN-2022. These Ordinary Shares will be under lockup for 351 days starting from 8-JUL-2021 to 24-JUN-2022.
Details:
The sponsors of the Company shall retain their entire shareholding in the Company for a period of not less than twelve months from the last date of public subscription.
The sponsors of the Company shall retain not less than twenty five percent of the post issue paid up capital of the Company for not less than three financial years from the last date of the public subscription.
The sponsors of the company are Mr. Nadeem Ahmad, Mr. Rizwan Ahmad, Mr. Muhammad Naeem, Mr. Naveed Amjad, and Mr. Ateeq ur Rehman. They own 53,999,988, 40,500,000, 13,500,000, 13,500,000, and 13,500,000 shares, respectively.
Citi Pharma Limited is a Pakistan-based pharmaceutical company. The principal activity of the Company is manufacturing and sale of pharmaceuticals, medical chemicals, and botanical products. The Company's departments include API, formulation, and research and development. Its key products under the API segment include Paracetamol, Amoxicillin, Levofloxacin, Cefixime, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, Ibuprofen, and Ascorbic acid. The Company's formulation department produces tablets, liquids, and capsules. Its research and development activities deal with various forms ranging from the development of new chemical/drug entities to the evaluation of existing products for alternative indications. Its other products include Amlodopine, Nimesulide, Mefenamic Acid, Simvastatin, Ranitiddine as Hcl, and Levofloxicen(as Hemihydrate), among others.
CITI PHARMA LIMITED 
